Sensei Biotherapeutics (NASDAQ:FTH) Given “Buy” Rating at BTIG Research

Sensei Biotherapeutics (NASDAQ:FTH)‘s stock had its “buy” rating reiterated by equities research analysts at BTIG Research in a report released on Thursday,Benzinga reports. They presently have a $55.00 price objective on the stock. BTIG Research’s price target indicates a potential upside of 74.77% from the stock’s previous close.

FTH has been the topic of a number of other reports. Robert W. Baird assumed coverage on shares of Sensei Biotherapeutics in a research report on Friday, June 26th. They issued an “outperform” rating and a $57.00 target price on the stock. Weiss Ratings started coverage on shares of Sensei Biotherapeutics in a research note on Wednesday, June 17th. They set a “sell (d-)” rating on the stock. Finally, HC Wainwright began coverage on shares of Sensei Biotherapeutics in a research note on Monday, June 22nd. They set a “buy” rating and a $60.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $57.33.

Sensei Biotherapeutics Stock Down 5.0%

Shares of FTH opened at $31.47 on Thursday. The stock has a market capitalization of $42.23 million, a price-to-earnings ratio of -0.22 and a beta of -0.26. Sensei Biotherapeutics has a one year low of $6.32 and a one year high of $37.90.

Sensei Biotherapeutics (NASDAQ:FTH) last posted its earnings results on Friday, May 15th. The company reported ($131.45) earnings per share for the quarter. Sell-side analysts predict that Sensei Biotherapeutics will post -16.61 EPS for the current fiscal year.

Insider Transactions at Sensei Biotherapeutics

In other news, CEO Anand Kiran Parikh bought 2,806 shares of the firm’s stock in a transaction on Monday, June 22nd. The stock was acquired at an average cost of $19.76 per share, with a total value of $55,446.56. Following the completion of the acquisition, the chief executive officer owned 764,234 shares of the company’s stock, valued at approximately $15,101,263.84. This represents a 0.37% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Brian C. Stephenson purchased 9,391 shares of the business’s stock in a transaction dated Wednesday, June 24th. The shares were purchased at an average price of $26.13 per share, for a total transaction of $245,386.83. Following the acquisition, the chief financial officer owned 26,804 shares of the company’s stock, valued at approximately $700,388.52. The trade was a 53.93% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders purchased 49,494 shares of company stock worth $1,188,822. 7.00% of the stock is currently owned by company insiders.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.

Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.